Myoroxa 10 mg/15 mg/20 mg FC tablets
PDF Leaflet Revision Date: 18 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of VTE and treatment of DVT/PE.
Dosage (summary)
10 mg once daily for VTE prevention; 15 mg twice daily for DVT/PE treatment.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Other anticoagulants
Contraindications
- Active bleeding
- Hepatic disease
- Severe renal impairment
Common side effects
- Anaemia
- Dizziness
- Gingival bleeding
Counselling Points
- Take with food for 15 mg and 20 mg
- Monitor for signs of bleeding
- Do not double doses for missed doses
Serious warnings
- Increased risk of thrombotic events on discontinuation
- Spinal/epidural haematoma risk
Important Disclaimer
The Myoroxa 10 mg/15 mg/20 mg FC tablets professional information leaflet below is the property of Ipharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
